![Review of precision therapeutics and emerging strategies in HR+ MBC](https://oncodaily.com/pub/uploads/2024/08/Maxwell-e1724769861924.png)
Photo taken from Maxwell Lloyd/X
Aug 27, 2024, 17:21
Review of precision therapeutics and emerging strategies in HR+ MBC
Michelle DeMeo, Senior Program Manager at Dana-Farber Cancer Institute, shared on X:
“Congratulations to Maxwell Lloyd, Kevin Kalinsky, Aditya Bardia, Komal Jhaveri and Seth Wander for recently published review of precision therapeutics and emerging strategies in HR+ MBC (metastatic breast cancer) in Nature Reviews Clinical Oncology.”
Precision therapeutics and emerging strategies for HR-positive metastatic breast cancer
Authors: Maxwell Lloyd, Kevin Kalinsky, Aditya Bardia, Komal Jhaveri and Seth Wander.
Source: Michelle DeMeo/X
Aug 27, 2024, 16:41